Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	333.87	233.18	145.24	109.46	131.84	198.32
Revenue Growth (YoY)	87.94%	60.55%	32.69%	-16.97%	-33.52%	13.11%
Cost of Revenue	220.38	225.24	256.44	231.75	204.98	137.9
Gross Profit	113.49	7.94	-111.2	-122.29	-73.14	60.42
Selling, General & Admin	284.18	264.12	265.54	197.52	126.28	135.8
Operating Expenses	284.18	264.12	265.54	197.52	126.28	135.8
Operating Income	-170.69	-256.18	-376.74	-319.81	-199.43	-75.38
Interest Expense	-11.3	-11.18	-11.33	-11.01	-19.68	-19.05
Interest & Investment Income	14.45	17.82	21.77	6.28	1.99	5
Earnings From Equity Investments	-3.4	-3.4	-	-	-	-
Currency Exchange Gain (Loss)	-0.7	-0.7	0.5	1.4	0.3	1.2
Other Non Operating Income (Expenses)	4.06	0.78	1.09	-0.43	-0.07	0.22
EBT Excluding Unusual Items	-167.57	-252.87	-364.72	-323.58	-216.88	-88
Merger & Restructuring Charges	-1.53	-2.44	-11.39	-	-	-
Other Unusual Items	-	-	-	-7.58	-	-3.66
Pretax Income	-169.1	-320.51	-376.11	-331.16	-216.88	-188.79
Income Tax Expense	-0.1	0.12	0.22	0.31	0.41	-19.36
Earnings From Continuing Operations	-169	-320.63	-376.33	-331.47	-217.29	-169.43
Earnings From Discontinued Operations	-0.06	-0.92	264.93	52.99	37.2	-
Net Income	-169.06	-321.55	-111.4	-278.48	-180.09	-169.43
Net Income to Common	-169.06	-321.55	-111.4	-278.48	-180.09	-169.43
Shares Outstanding (Basic)	85	79	74	64	60	48
Shares Outstanding (Diluted)	85	79	74	64	60	48
Shares Change (YoY)	10.00%	6.22%	16.48%	6.56%	25.86%	12.28%
EPS (Basic)	-2.00	-4.08	-1.50	-4.37	-3.01	-3.56
EPS (Diluted)	-2.00	-4.08	-1.50	-4.37	-3.01	-3.56
Free Cash Flow	-115.59	-237.48	-280.02	-186.29	-19.89	-49.51
Free Cash Flow Per Share	-1.37	-3.01	-3.77	-2.92	-0.33	-1.04
Gross Margin	33.99%	3.40%	-76.57%	-111.72%	-55.48%	30.47%
Operating Margin	-51.13%	-109.87%	-259.40%	-292.17%	-151.27%	-38.01%
Profit Margin	-50.64%	-137.90%	-76.70%	-254.41%	-136.60%	-85.43%
Free Cash Flow Margin	-34.62%	-101.84%	-192.80%	-170.19%	-15.09%	-24.96%
EBITDA	-120.54	-212.63	-338.21	-299.09	-186.68	-50.8
EBITDA Margin	-36.10%	-91.19%	-232.87%	-273.25%	-141.60%	-25.61%
D&A For EBITDA	50.15	43.56	38.53	20.72	12.75	24.58
EBIT	-170.69	-256.18	-376.74	-319.81	-199.43	-75.38
EBIT Margin	-51.12%	-109.87%	-259.40%	-292.17%	-151.27%	-38.01%
Revenue as Reported	333.87	233.18	145.24	109.46	131.84	198.32

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q